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Abstract
Jayson GC et al. remarked in Lancet that nearly 100% of mucinous ovarian cancer cases have Kras mutation as
well as a high frequency of Her2 amplification. Using the Abbott PathVysion Her2 DNA Probe Kit and Kras mutant-
enriched PCR Kits (FemtoPath®), 21 samples of primary ovarian mucinous cystadenocarcinomas from Taiwanese
patients were examined to determine the status of Her2 amplification and Kras mutations. Our results showed the
Her2 amplification rates were 33.33%, while the Kras mutation rates were 61.90%. We present here our results in
order to enlighten the readership that the ~100% Kras mutant frequency and the high Her2 amplification rate
reported by Jayson et al. may be too exaggerated to be applicable into all populations. Additionally, we report
another 2 novel Kras mutations (A11V, V14I).
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Main text
We read with great interest the work by Jayson et al. in
Lancet (Oct. 2014). The authors presented a comprehen-
sive review of outstanding quality. They remarked that
mucinous ovarian carcinoma has a nearly 100% human V-
Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (Kras)
mutation as well as a high frequency of human epidermal
growth factor receptor 2 (Her2) amplification [1]. However,
we respectfully disagree with Jayson et al.’s opinion.
Literature reviews revealed that in mucinous ovarian
carcinoma, the frequency of Her2 amplification/over-ex-
pression is estimated to be between 18 and 35% [2], and
the presence of human Kras mutations is 13 to 60% [3–5].
This preliminary report aims to enlighten the readership
that the ~100% Kras mutant frequency and the high Her2
amplification rate in mucinous ovarian carcinoma may be
higher than what has been observed in other studies,
including our own.
Briefly, genomic DNA was extracted from formalin-
fixed, paraffin-embedded tissue blocks of 21 cases of
mucinous ovarian carcinoma. All the donors’ identities
have been permanently deleted. Abbott PathVysion Her2
DNA Probe Kit and the 2013 American Society of Clinical
Oncology/College of American Pathologists (ASCO/CAP)
breast cancer scoring methods were used to examine for
Her2 FISH ratio. The Kras mutant-enriched polymerase
chain reaction (PCR) Kits (FemtoPath®) and a following
direct sequencing method were applied to analyze exon 2
of the Kras gene. The reason why we choose Kras exon 2
to analyze is because Kras gene mutations are mainly
known to cluster in several hotspots, with exon 2 (codons
12 and 13) being most commonly affected [6–9].
The prevalence of Kras mutations and Her2 amplifica-
tion within 21 Taiwanese mucinous ovarian carcinoma
cases is shown in Table 1, which indicates that the
amplification rate of Her2 was 33.33% (n = 7), while the
mutation rate of Kras was 61.90% (n = 13). Additionally,
the rates of co-existing Kras mutations and Her2 ampli-
fication were 9.52% (n = 2) (Table 1). However, there was
a lack of statistically significant association between
Her2 amplification and Kras mutations (p = 0.057).
Of the 13 cases of mucinous ovarian carcinoma with
Kras mutations, 12 cases had a single missense muta-
tion, which was composed of G12V in 4 cases, G12D in
5 cases, G12A in 1 case and A11V in 2 cases. The
remaining 1 case had triple missense mutations—A11V,
G13N and V14I. Moreover, both A11V and V14I were
novel discoveries, based on the Catalogue of Somatic
Mutations in Cancer (COSMIC) database [10].
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Conclusion
Both Her2 amplification and Kras activating mutations are
not mutually exclusive, which indicates that Her2/Kras/
mitogen-activated protein kinases (MAPK) is a crucial
pathway in the carcinogenesis of mucinous ovarian neo-
plasms. Targeting this pathway seems to be a viable thera-
peutic option for patients with recurrent or advanced
stage mucinous ovarian carcinoma. Treatment selection
based on the molecular alterations of Her2 and Kras can
possibly produce superior therapeutic effects compared
with nonselective treatments. Additionally, functional im-
pacts of these 2 novel Kras mutations (A11V, V14I) are
still unknown; further studies using bioinformatics tools
and molecular modeling are encouraged.
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Table 1 The prevalence and relationship of Kras mutations and
Her2 amplification in mucinous ovarian carcinoma
Her2 non-amplification Her2 amplification Total
n (%) n (%) n (%)
Kras wild type 3 (14.29) 5 (23.81) 8 (38.10)
Kras mutation 11 (52.38) 2 (9.52) 13 (61.90)
Total 14 (66.67) 7 (33.33) 21 (100.00)
P value 0.056a
n (%) number (percentage)
aFisher’s exact test
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